Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2020 10/14/2020 10/15/2020 10/16/2020 10/19/2020 Date
123.75(c) 122.52(c) 122.03(c) 124.13(c) 121.76 Last
1 461 461 1 883 948 1 474 412 4 251 190 1 623 022 Volume
-0.51% -0.99% -0.40% +1.72% -1.91% Change
More quotes
Financials (USD)
Sales 2020 5 753 M - -
Net income 2020 329 M - -
Net Debt 2020 77,6 M - -
P/E ratio 2020 84,2x
Yield 2020 -
Sales 2021 6 396 M - -
Net income 2021 2 153 M - -
Net cash position 2021 1 365 M - -
P/E ratio 2021 12,3x
Yield 2021 -
Capitalization 27 206 M 27 206 M -
EV / Sales 2020 4,74x
EV / Sales 2021 4,04x
Nbr of Employees 3 082
Free-Float 91,3%
More Financials
Company
Alexion Pharmaceuticals, Inc. specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. At the end of 2019, the group had a portfolio of 6 products in clinical development. Net sales are distributed geographically as follows: the United States (55.6%), Europe (24.2%), Asia/Pacific (10.6%) and other (9.6%). 
Sector
Pharmaceuticals
Calendar
10/22Earnings Release
More about the company
Notations Surperformance© of Alexion Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ALEXION PHARMACEUTICALS, INC.
02:15pALEXION PHARMACEUTICALS, INC. : quaterly earnings release
10/13ALEXION PHARMACEUTICALS : Receives FDA Approval for New Advanced Formulation of ..
AQ
10/12ALEXION PHARMACEUTICALS : Announces Upcoming Data Presentations at the American ..
AQ
10/12ALEXION PHARMACEUTICALS : Receives FDA Approval for New Advanced Formulation of ..
BU
10/09ALEXION PHARMACEUTICALS : Announces Upcoming Data Presentations at the American ..
BU
10/07ALEXION PHARMACEUTICALS : Highlights Promising Pipeline & Distinguished Rare Dis..
AQ
10/06ALEXION PHARMACEUTICALS : Highlights Promising Pipeline & Distinguished Rare Dis..
BU
10/01ALEXION PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
AQ
09/28ALEXION PHARMACEUTICALS : ULTOMIRIS Receives Approval in Japan for Atypical Hemo..
AQ
09/25ALEXION PHARMACEUTICALS : ULTOMIRIS® (ravulizumab) Receives Approval in Japan fo..
BU
09/22ALEXION PHARMACEUTICALS : Receives CHMP Positive Opinion for New Advanced Formul..
AQ
09/21ALEXION PHARMACEUTICALS : Receives CHMP Positive Opinion for New Advanced Formul..
BU
09/15ALEXION PHARMACEUTICALS : to Discuss Key Pipeline Programs at Virtual Investor D..
AQ
09/15ALEXION PHARMACEUTICALS : and Caelum Biosciences Announce Start of Phase 3 Studi..
AQ
09/14ALEXION PHARMACEUTICALS : and Caelum Biosciences Announce Start of Phase 3 Studi..
BU
More news
News in other languages on ALEXION PHARMACEUTICALS, INC.
02:45aALEXION PHARMACEUTICALS, INC. : Veröffentlichung des Quartalsergebnisses
02:45aALEXION PHARMACEUTICALS, INC. : publication des résultats trimestriels
10/06Aktien New York: Standardwerte rücken weiter vor
10/06Aktien New York: Standardwerte rücken weiter vor
10/06Aktien New York Ausblick: Dow könnte an Vortagesrally anknüpfen
More news
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 145,32 $
Last Close Price 124,13 $
Spread / Highest target 41,0%
Spread / Average Target 17,1%
Spread / Lowest Target -5,74%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
Aradhana Sarin President & Director
David Richard Brennan Chairman
Brian M. Goff Chief Commercial, Global Operations Officer & EVP
John J. Orloff Executive VP, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS, INC.14.78%27 206
CSL LIMITED8.43%96 384
BIOGEN INC.-5.63%44 329
SAMSUNG BIOLOGICS CO.,LTD.58.66%39 798
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.226.14%38 693
WUXI BIOLOGICS (CAYMAN) INC.107.20%35 823